Clinical Trial Update: Single Arm Romiplostim to Prevent CIT [EARLY_Phase 1]

View source ↗

Summary

A single-arm Phase 1 trial is evaluating romiplostim to prevent chemotherapy-induced thrombocytopenia in patients with Ewing sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Thrombocytopenia
• Ewing Sarcoma

Drugs mentioned

• Nplate (romiplostim)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Ewings Sarcoma, Chemotherapy Induced Thrombocytopenia | EARLY_Phase 1 | Status: RECRUITING